Coalition for Pulmonary Fibrosis

Coalition for Pulmonary Fibrosis
Name	Coalition for Pulmonary Fibrosis
Formation	2000s
Type	Nonprofit
Headquarters	United States
Focus	Pulmonary fibrosis, interstitial lung disease

Coalition for Pulmonary Fibrosis is a United States-based nonprofit advocacy and research organization focused on pulmonary fibrosis and related interstitial lung diseases. The organization convenes patient groups, clinical researchers, pharmaceutical stakeholders and policy makers to accelerate diagnosis, treatment and awareness of fibrotic lung disorders. It works at the intersection of patient advocacy, biomedical research, public policy and clinical care.

Overview

The Coalition assembles a network of patient advocacy groups such as American Lung Association, Pulmonary Fibrosis Foundation, Alveolar Proteinosis Alliance, and clinical research centers including National Institutes of Health, U.S. Food and Drug Administration, Mayo Clinic, and Cleveland Clinic to align priorities for clinical trial design, biomarker development and patient-reported outcomes. It engages stakeholders from pharmaceutical companies like Roche, Boehringer Ingelheim, Bristol Myers Squibb, and academic institutions such as Johns Hopkins University, Harvard Medical School, University of California, San Francisco, and University of Pennsylvania to translate basic science into therapies. The Coalition liaises with policy bodies including Centers for Medicare & Medicaid Services, U.S. Congress, World Health Organization, and regulatory consortia like the International Council for Harmonisation on matters affecting access to care and research funding.

History and Formation

Founded in the early 21st century amid rising interest in fibrotic lung disease, the Coalition emerged from collaborative efforts among clinicians at centers such as Brigham and Women's Hospital, researchers at National Heart, Lung, and Blood Institute, patient advocates from organizations like American Thoracic Society members and industry stakeholders including Genentech and GlaxoSmithKline. Early convenings included representatives from European Respiratory Society, American College of Chest Physicians, and foundations such as the Wellcome Trust to set priorities for diagnostic standardization and data sharing. Over time, the Coalition formalized governance structures influenced by nonprofit models used by groups like Bill & Melinda Gates Foundation and Robert Wood Johnson Foundation to scale advocacy and research programs.

Mission and Activities

The Coalition's stated mission emphasizes improving outcomes for people affected by fibrotic lung disease through research support, public policy advocacy, education and community building. Activities include organizing consensus meetings with stakeholders from National Institutes of Health, convening advisory panels with experts from Stanford University School of Medicine and Columbia University Irving Medical Center, and producing guidance used by clinicians at institutions such as Mount Sinai Health System. It runs outreach campaigns aligned with awareness observances like Rare Disease Day and coordinates with patient registries modeled on efforts at European Lung Foundation and All of Us Research Program to harmonize data collection.

Research and Advocacy Initiatives

Research initiatives spearheaded by the Coalition promote multicenter clinical trial networks, natural history studies, and biomarker validation in collaboration with entities such as Translational Research Institute, National Center for Advancing Translational Sciences, and academic consortia including Clinical and Translational Science Awards. Advocacy efforts target legislation and reimbursement policies debated in U.S. Congress, briefings with Centers for Medicare & Medicaid Services, and engagement with international regulators including European Medicines Agency to expedite approval pathways. The Coalition supports patient-centered outcome research influenced by methods from Patient-Centered Outcomes Research Institute and fosters publication of consensus statements in journals affiliated with American Thoracic Society and European Respiratory Journal.

Partnerships and Collaborations

Strategic partnerships include collaborations with pharmaceutical developers such as AstraZeneca, biotechnology firms like Vertex Pharmaceuticals, and diagnostics companies modeled on partnerships seen with Abbott Laboratories. Academic collaborators encompass medical centers including UCLA Health, Yale School of Medicine, University of Michigan, and international partners such as Imperial College London and University of Toronto. The Coalition networks with global advocacy organizations including Global Lung Initiative exemplars and works alongside registries and biobanks inspired by UK Biobank and Allergy and Asthma Network to enable translational research.

Funding and Governance

Funding for the Coalition derives from a combination of philanthropic grants, industry partnerships with firms such as Pfizer and Eli Lilly and Company, and foundation support patterned on grants from donors like Charles H. Hood Foundation and Kresge Foundation. Governance structures reflect nonprofit best practices with a board comprising clinicians from Massachusetts General Hospital, researchers from Fred Hutchinson Cancer Research Center, patient advocates, and industry representatives. Financial oversight and compliance draw on standards promulgated by entities like Internal Revenue Service (for U.S. nonprofits) and accounting frameworks used by Grantmakers in Health.

Impact and Recognition

The Coalition has influenced clinical practice guidelines developed with societies such as American Thoracic Society and European Respiratory Society, contributed to multicenter trials that informed approvals by U.S. Food and Drug Administration and European Medicines Agency, and advanced patient engagement models cited by Patient-Centered Outcomes Research Institute. Recognition has come from awards and citations within networks such as National Academy of Medicine forums, conference presentations at American Thoracic Society International Conference, and collaborative publications with leading institutions like Johns Hopkins University and Mayo Clinic. The Coalition's work continues to shape research agendas, policy discussions and community support for people living with fibrotic lung disease.

Category:Pulmonology organizations